A pharmaceutical composition for oral administration comprising an active substance having a food effect, in combination with a lipid material comprising membrane lipids, characterised in showing a reduced food effect.

22

- The pharmaceutical composition according to claim 1, wherein the content of membrane lipids is not less than 3
 % by weight of the lipid material.
- 3. The pharmaceutical composition according to claim 1 or 2, wherein the membrane lipids contain digalactosyldiacylglycerol in an amount not less than about 0.5 % by weight of the lipid material.
 - 4. The pharmaceutical composition according to any of claims 1-3, wherein the lipid material comprises a fractionated cereal oil, preferably from oats.
- 5. The pharmaceutical composition according to any of claims 1-4, wherein the lipid material comprises non-polar lipids.
- 25 6. The pharmaceutical composition according to any of the preceding claims, wherein the composition comprises the active substance dissolved or dispersed in solid lipid particles with a diameter of not more than 20 µm.
- 7. A pharmaceutical composition for oral administration comprising from 0.5 to 12 % by weight of the composition, preferably 1 to 8 %, of isotretinoin, and a lipid material comprising from 2 % to 60 % by weight of membrane lipids, and from 30 to 98 % by weight of non-polar lipids, calculated on the lipid material.
- 8. A pharmaceutical composition for oral administration comprising from 0.1 to 20 % by weight of an immunosuppressant, from 1 % to 40 % by weight of membrane lipids, and from 5 to 40 % by weight of monoglycerides, calculated on the composition.
- A pharmaceutical composition for oral administration comprising up to about 50 % by weight of an antiviral,
 from about 10 % to about 70 % by weight of membrane lipids, and from about 10 % to about 70 % by weight of monoglycerides, calculated on the composition.

- 10. The pharmaceutical composition according to any of the preceding claims, wherein the lipid material comprises about 3 % to about 60 % by weight of monoglycerides.
- 5 11. The pharmaceutical composition according to any of claims 8-10, wherein the monoglycerides comprise medium chain monoglycerides.
- 12. The pharmaceutical composition according to any of the preceding claims, wherein the lipid material comprises at least 10 % by weight of di- and triglycerides or a mixture thereof.
- 13. The pharmaceutical composition according to any of the preceding claims comprising in addition a polar solvent.
 - 14. A pharmaceutical composition comprising solid lipid particles with a diameter of not more than about 20 $\mu\text{m}\textsc{,}$ comprising
- 20 a) an active substance, dissolved or dispersed in said lipid particles, and
 - b) a lipid material comprising membrane lipids.
- 15. The pharmaceutical composition according to any of the 25 preceding claims, showing a reduced food effect of at least 25 %.
 - 16. The pharmaceutical composition according to any of the preceding claims, having a food effect less than 20 %.
 - 17. Use of a lipid material comprising membrane lipids for the manufacture of a pharmaceutical composition according to any of the preceding claims having a reduced food effect.

35

30

40

45